<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02748135</url>
  </required_header>
  <id_info>
    <org_study_id>ONC-403-001</org_study_id>
    <nct_id>NCT02748135</nct_id>
  </id_info>
  <brief_title>A Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma</brief_title>
  <official_title>A Phase 1, Open-Label, Multicenter, Dose Escalation Study of TB-403 in Pediatric Subjects With Relapsed or Refractory Medulloblastoma, Neuroblastoma, Ewing Sarcoma or Alveolar Rhabdomyosarcoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Oncurious NV</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>BioInvent International AB</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Beat Childhood Cancer</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Oncurious NV</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability profile of TB-403
      (humanized monoclonal antibody against placental growth factor (PlGF)) in pediatric subjects
      with relapsed or refractory Medulloblastoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The maximum tolerated dose of TB-403 will be determined in pediatric subjects with relapsed
      or refractory Medulloblastoma (MB) and as well Neuroblastoma (NB), Ewing Sarcoma (ES) and
      Alveolar Rhabdomyosarcoma (ARMS).
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date>May 2016</start_date>
  <completion_date type="Anticipated">March 2023</completion_date>
  <primary_completion_date type="Anticipated">June 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The primary safety endpoint will be the determination of the maximum tolerated dose (MTD) / study maximum dose (SMD) based on the occurrence of dose-limiting toxicities (DLTs) during the 28-day DLT assessment period.</measure>
    <time_frame>Day28</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>TB-403 total exposure (AUC∞) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Dose/CL after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Volume of the central compartment (Vc) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 Volume of distribution at steady-state (Vss) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>TB-403 terminal half-life (t½,z) after single ascending dose</measure>
    <time_frame>Day 1, day 4, day 8, day 15, day 29, day 60, day 90, day 165 and day 195.</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">24</enrollment>
  <condition>Relapsed or Refractory Medulloblastoma (MB), Neuroblastoma (NB), Ewing Sarcoma (ES) and Alveolar Rhabdomyosarcoma (ARMS)</condition>
  <arm_group>
    <arm_group_label>TB-403 20mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 50mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 100mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>TB-403 175mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 20mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 20mg/kg</description>
    <arm_group_label>TB-403 20mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 50mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 50mg/kg</description>
    <arm_group_label>TB-403 50mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 100mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 100mg/kg</description>
    <arm_group_label>TB-403 100mg/kg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TB-403 175mg/kg</intervention_name>
    <description>bi-weekly intravenous doses of TB-403 175mg/kg</description>
    <arm_group_label>TB-403 175mg/kg</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Provide written informed consent (Subject or legal representative)

          2. Be &gt; 6 months and &lt; 18 years of age

          3. Have a histologically-confirmed diagnosis of MB, NB, ES, or ARMS

          4. Have documented relapse or refractoriness after standard-of-care therapy

          5. Have undergone magnetic resonance imaging (MRI) for MB (brain [all cohorts] and spinal
             cord [cohort 4 only], a computerized tomography (CT) / metaiodobenzylguanidine (MIBG)
             scan for NB, and CT / magnetic resonance imaging (MRI) for ES or ARMS within 1 month
             prior to first dose of study treatment

          6. Have a Lansky score ≥ 40 for subjects up to 16 years of age or a Karnofsky score ≥ 40
             for subjects 16 years of age to &lt; 18 years

          7. Have adequate organ function, defined as:

               -  Peripheral absolute neutrophil count ≥ 1.5 × 10^9/L

               -  Platelet count ≥ 100 × 10^9/L

               -  Hemoglobin ≥ 8mg/dL (transfusion to reach this level is permitted)

               -  International normalized ratio (INR) &lt; 1.5; partial thromboplastin time (PTT) &lt;
                  1.5 upper limit of normal (ULN)

               -  Creatinine clearance &gt; 50mL/min/1.73m2 or serum creatinine ≤ specified maximum
                  values based on age, as described below:

               -  6 months to 3 years of age: serum creatinine ≤ 0.4mg/dL

               -  3 to 13 years of age: serum creatinine ≤ 0.7mg/dL

               -  &gt; 13 years of age: serum creatinine ≤ 1mg/dL

               -  Serum aspartate aminotransferase (AST) and serum alanine aminotransferase (ALT) &lt;
                  2.5 × ULN; serum bilirubin &lt; 1.5 × ULN

          8. Have no symptoms of cranial hypertension or convulsions within 14 days before Cycle 1
             Day 1 (anti-epileptic drugs and corticoids are allowed to control any preexisting
             symptoms)

          9. If female of child bearing potential, must not be lactating and must have a negative
             pregnancy test (blood or urine, at the discretion of the investigator) prior to
             enrollment and use effective contraception during study participation. Women should
             continue effective contraception for 3 months following last dose of TB-403.

         10. If a sexually-active male, must agree to use a latex condom during any sexual contact
             with females of child bearing potential while participating in the study and for 3
             months following last dose of TB-403.

         11. For subjects on corticosteroids for endocrine deficiencies or tumor-associated
             symptoms, must be on a stable (or decreasing) dose for at least 7 days before first
             dose of study treatment.

        Exclusion Criteria:

          1. Have any clinically significant disease considered by the investigator to interfere
             with study participation

          2. Have not fully recovered from the acute toxic effects of prior anticancer therapy
             (e.g., chemotherapy, immunotherapy, radiation therapy) or are currently receiving
             cytotoxic chemotherapy, immunotherapy or radiation therapy. Subjects must be within
             the following timelines relative to first dose of study treatment:

               -  Myelosuppressive chemotherapy: Must not have received within 2 weeks (6 weeks if
                  prior nitrosourea)

               -  Hematopoietic growth factors: At least 5 days since the completion of therapy
                  with a growth factor

               -  Biologic (anti-neoplastic agent): At least 7 days since the completion of therapy
                  with a biologic agent. For agents that have known adverse events occurring beyond
                  7 days after administration, this period must be extended beyond the time during
                  which adverse events are known to occur. The duration of this interval must be
                  discussed with the Sponsor

               -  Immunotherapy: At least 6 weeks since the completion of any type of
                  immunotherapy, e.g., tumor vaccines

               -  Monoclonal antibodies: At least 7 days or 3 half-lives, whichever is longer, must
                  have elapsed since prior treatment with a monoclonal antibody

               -  Radiotherapy: At least 14 days since the last treatment except for radiation
                  delivered with palliative intent to a non-target site

               -  Stem Cell Transplant or Rescue: No evidence of active graft vs. host disease and
                  ≥ 2 months must have elapsed since transplant

          3. Have participated in another therapeutic clinical trial with an investigational drug
             within 1 month before first dose of study treatment

          4. Have any known active uncontrolled infection

          5. Have had major surgery or bone fracture within 28 days before first dose of study
             treatment

          6. Have previously received TB-403

          7. Have a history of severe allergic or anaphylactic reactions or hypersensitivity to
             recombinant proteins or excipients in the investigational drug

          8. Are receiving increasing doses of corticosteroids

          9. Are eligible for a curative treatment option

         10. Have had a prior thrombotic event (e.g., pulmonary embolism, deep vein thrombosis) or
             are currently receiving therapeutic or prophylactic doses of anticoagulants.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>6 Months</minimum_age>
    <maximum_age>18 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Study Director, Global Clinical Development</last_name>
    <phone>+32 16 751 310</phone>
    <email>info@oncurious.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Little Rock</city>
        <state>Arkansas</state>
        <zip>72202</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Oakland</city>
        <state>California</state>
        <zip>94609</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hartford</city>
        <state>Connecticut</state>
        <zip>06106</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02115</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Grand Rapids</city>
        <state>Michigan</state>
        <zip>49503</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63104</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78723</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75235</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.oncurious.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>April 2020</verification_date>
  <study_first_submitted>April 8, 2016</study_first_submitted>
  <study_first_submitted_qc>April 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 22, 2016</study_first_posted>
  <last_update_submitted>April 1, 2020</last_update_submitted>
  <last_update_submitted_qc>April 1, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">April 3, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sarcoma</mesh_term>
    <mesh_term>Neuroblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma</mesh_term>
    <mesh_term>Sarcoma, Ewing</mesh_term>
    <mesh_term>Medulloblastoma</mesh_term>
    <mesh_term>Rhabdomyosarcoma, Alveolar</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antibodies, Monoclonal</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

